Pharmacokinetics of halofantrine in the rat: Stereoselectivity and interspecies comparisons

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 3, 1999, Pages 165-169

  Brocks, Dion R ^a   Toni, Jason W ^b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Halofantrine; Plasma; Stereoselectivity

Indexed keywords

HALOFANTRINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ENANTIOMER; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RACEMIC MIXTURE; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPECIES DIFFERENCE; STEREOCHEMISTRY; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; STEREOISOMERISM;

EID: 0033031151     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199904)20:3<165::AID-BDD170>3.0.CO;2-Z     Document Type: Article

References (21)

1. Bryson HM and Goa KL. Halofantrine; a review of its anti-malarial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 43: 236-258.
2. Basco LK, Gillotin C, Gimenez F, Farinotti R and Le Bras J. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol 1992; 33: 517-520.
3. Karle JM, Olmeda R, Gerena L and Milhous WK. Plasmodium faldparum: Role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial drugs. Exp Parasitol 1993; 76: 345-351.
4. Gimenez F, Aubry AF, Farinotti R, Kirkland R and Wainer IW. The determination of the enantiomers of halofantrine and monodesbutylhalofantrine in plasma and whole blood using sequential achiral/chiral high performance liquid chromatography. J Chramatogr 1992; 10: 245-250.
5. Brocks DR, Dennis MJ and Schaefer WH. A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. J Pharm Biomed Anal 1995; 13: 911-918.
6. Gimenez F, Gillotin C, Basco LK, Bouchaud O, Aubry AF, Wainer IW, Le Bras J and Farinotti R. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol 1994; 46: 561-562.
7. Karbwang J and Bangchang KN. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 1994; 27: 104-119.
8. Milton KA, Edwards G, Ward SA, Orme MLE and Breckenridge AM. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 1989; 28: 71-77.
9. Humberstone AJ, Porter CJH and Charman WN. A physiochemical basis for the effect of food on the absolute bioavailability of halofantrine. J Pharm Sci 1996; 85: 525-529.
10. Molun E, Le Metayer P and Szwandt S. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med 1995; 89: 430-433.
11. Giudicelli CP, Touze JE and Bernard J. Electrocardiographic changes in antimalarial treatment with halofantrine, pharmacokinetic study, therapeutic deductions. J Bull Acad Nat Med 1996; 180: 71-82.
12. Karle JM. X-Ray crystal structure of the antimalarial agent (-)-halofantrine hydrochloride supports stereospecificity for cardiotoxicity. Antimicrob Agents Chemother 1997; 41: 791-794.
13. Porter CJH, Charman SA and Charman WN. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: Effect of lipid vehicle dispersion. J Pharm Sci 1996; 85: 351-356.
14. Porter CJH, Charman SA, Humberstone AJ and Charman WN. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J Pharm Sci 1996; 85: 351-356.
15. Toni JW and Brocks DR. Stereospecific high performance liquid chromatographic (HPLC) analysis of halofantrine enantiomers in rat plasma. Pharm Res 1997; 14 (Suppl.): 568.
16. Krishna S, ter Kuile F, Supanaranond W, Pukrittayakamee S, Teja-Isavadharm P, Kyle D and White NJ. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br J Clin Pharmacol 1993; 36: 585-591.
17. Gibaldi M and Perrier D. Pharmacokinetics, 2nd edn. New York: Dekker, 1982.
18. Davies B and Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
19. Terefe H and Blaschke G. Direct determination of the enantiomers of halofantrine and its pharmacologically active metabolite N-desbutylhalofantrine by high performance liquid chromatography. J Chromatogr 1993; 615: 347-351.
20. Humberstone AJ, Porter CJH, Edwards GA and Charman WN. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J Pharm Sci 1998; 87: 936-942.
21. Szandt ISF, Edwards G and Ward SA. Factors affecting the bioavailability of halofantrine in the rat. Proceedings of the British Pharmacological Society, 14-16 April, 1993; 159P.